A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive

British Journal of Surgery

Volumn 95, Issue 3, 2008, Pages 302-309

  Pal, A ^a   Provenzano, E ^a   Duffy, S W ^b   Pinder, S E ^a   Pumshotham, A D ^c,d  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; NOMOGRAM; PRIORITY JOURNAL; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME; BREAST TUMOR; EVALUATION; LUNG CARCINOMA; LYMPH NODE; PAGET NIPPLE DISEASE; PATHOLOGY; PREDICTION AND FORECASTING; ROC CURVE; SENSITIVITY AND SPECIFICITY; STANDARD;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY;

EID: 40749113215     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5943     Document Type: Article

References (48)

1. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349: 546-553.
2. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997; 349: 1864-1867.
3. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C et al. The sentinel node in breast cancer - a multicenter validation study. N Engl J Med 1998; 339: 941-946.
4. Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276: 1818-1822.
5. Edge SB, Niland JC, Bookman MA, Theriault RL, Ottesen R, Lepisto E et al. Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. J Natl Cancer Inst 2003; 95: 1514-1521.
6. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006; 98: 599-609.
7. Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 2005; 23: 4312-4321.
8. Rutgers EJT, Meijnen P, Bonnefoi H. Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res 2004; 6: 165-169.
9. Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik A, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999; 229: 536-541.
10. Abdessalam SF, Zervos EE, Prasad M, Farrar WB, Yee LD, Walker MJ et al. Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am J Surg 2001; 182: 316-320.
11. van Iterson V, Leidenius M, Krogerus L, von Smitten K. Predictive factors for the status of non-sentinel nodes in breast cancer patients with tumor positive sentinel nodes. Breast Cancer Res Treat 2003; 82: 39-45.
12. Weiser MR, Montgomery LL, Tan LK, Susnik B, Leung DY, Borgen PI et al. Lymphovascular invasion enhances the prediction of non-sentinel node metastases in breast cancer patients with positive sentinel nodes. Ann Surg Oncol 2001; 8: 145-149.
13. Wong SL, Edwards MJ, Chao C, Turtle TM, Noyes RD, Woo C et al. Predicting the status of the nonsentinel axillary nodes: a multicenter study. Arch Surg 2001; 136: 563-568.
14. Dabbs DJ, Fung M, Landsittel D, McManus K, Johnson R. Sentinel lymph node micrometastasis as a predictor of axillary tumor burden. Breast J 2004; 10: 101-105.
15. Cserni G, Burzykowski T, Vinh-Hung V, Kocsis L, Boross G, Sinko M et al. Axillary sentinel node and tumour-related factors associated with non-sentinel node involvement in breast cancer. Jpn J Clin Oncol 2004; 34: 519-524.
16. Saidi RF, Dudrick PS, Remine SG, Mittal VK. Nonsentinel lymph node status after positive sentinel lymph node biopsy in early breast cancer. Am Surg 2004; 70: 101-105.
17. Barranger E, Coutant C, Flahault A, Delpech Y, Darai E, Uzan S. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat 2005; 91: 113-119.
18. den Bakker MA, van Weeszenberg A, de Kanter AY, Beverdam FH, Pritchard C, van der Kwast TH et al. Non-sentinel lymph node involvement in patients with breast cancer and sentinel node micrometastasis; too early to abandon axillary clearance. J Clin Pathol 2002; 55: 932-935.
19. Travagli JP, Atallah D, Mathieu MC, Rochard F, Camatte S, Lumbroso J et al. Sentinel lymphadenectomy without systematic axillary dissection in breast cancer patients: predictors of non-sentinel lymph node metastasis. Eur J Surg Oncol 2003; 29: 403-406.
20. Choi SH, Barsky SH, Chang HR. Clinicopathologic analysis of sentinel lymph node mapping in early breast cancer. Breast J 2001; 9: 153-162.
21. Callejo IP, BritoJA, BivarJW, Fernandes FJ, Faria JL, Andre MS et al. Predictors of positive axillary lymph nodes in breast cancer patients with metastatic sentinel lymph node. Clin Transl Oncol 2005; 7: 18-22.
22. Schrenk P, Konstantiniuk P, Wolfl S, Bogner S, Haid A, Nemes C et al. Prediction of non-sentinel lymph node status in breast cancer with a micrometastatic sentinel node. Br J Surg 2005; 92: 707-713.
23. Kamath VJ, Giuliano R, Dauway EL, Cantor A, Berman C, Ku NN et al. Characteristics of tile sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg 2001; 136: 688-692.
24. Cserni G, Gregori D, Merletti F, Sapino A, Mano MP, Ponti A et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg 2004; 91: 1245-1252.
25. Carcoforo P, Bergossi L, Basaglia E, Soliani G, Querzoli P, Zambrini E et al. Prognostic and therapeutic impact of sentinel node micrometastasis in patients with invasive breast cancer. Tumori 2002; 88: S4-S5.
26. Nos C, Harding-MacKean C, Freneaux P, Trie A, Falcou MC, Sastre-Garau X et al. Prediction of tumour involvement in remaining axillary lymph nodes when the sentinel node in a woman with breast cancer contains metastases. Br J Surg 2003; 90: 1354-1360.
27. Leidenius MH, Vironen JH, Riihela MS, Krogerus LA, Toivonen TS, von Smitten KA et al. The prevalence of non-sentinel node metastases in breast cancer patients with sentinel node micrometastases. Eur J Surg Oncol 2005; 31: 13-18.
28. Viale G, Maiorano E, Mazzarol G, Zurrida S, Galimberti V, Luini A et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 2001; 92: 1378-1384.
29. Fleming FJ, Kavanagh D, Crotty TB, Quinn CM, McDermott EW, O'Higgins N. Factors affecting metastases to non-sentinel lymph nodes in breast cancer. J Clin Pathol 2004; 57: 73-76.
30. Farshid G, Pradhan M, Kollias J, Gill PG. A decision aid for predicting non-sentinel node involvement in women with breast cancer and at least one positive sentinel node. Breast 2004; 13: 494-501.
31. Fournier K, Schiller A, Perry RR, Laronga C. Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection. Ann Surg 2004; 239: 859-863.
32. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 2006; 7: 983-990.
33. Changsri C, Prakash S, Sandweiss L, Bose S. Prediction of additional axillary metastasis of breast cancer following sentinel lymph node surgery. Breast J 2004; 10: 392-397.
34. Zavagno G, De Salvo GL, Bozza F, Scalco G, Marconato R, Valletta S et al. Number of metastatic sentinel nodes as predictor of axillary involvement in patients with breast cancer. Breast Cancer Res Treat 2004; 86: 171-179.
35. Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003; 10: 1140-1151.
36. Kocsis L, Svebis M, Boross G, Sinko M, Maraz R, Rajtar M et al. Use and limitations of a nomogram predicting the likelihood of non-sentinel node involvement after a positive sentinel node biopsy in breast cancer patients. Am Surg 2004; 70: 1019-1024.
37. Soni NK, Carmalt HL, Gillett DJ, Spillane AJ. Evaluation of a breast cancer nomogram for prediction of non-sentinel lymph node positivity. Eur J Surg Oncol 2005; 31: 958-964.
38. Reynolds C, Mick R, Donohue JH, Grant CS, Farley DR, Callans LS et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol 1999; 17: 1720-1726.
39. Goyal A, Douglas-Jones A, Newcombe RG, Mansel RE. ALMANAC Trialists Group. Predictors of non-sentinel lymph node metastasis in breast cancer patients. Eur J Cancer 2004; 40: 1731-1737.
40. Lambert LA, Ayers GD, Hwang RF, Hunt KK, Ross MI, Kuerer HM et al. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol 2006; 13: 310-320.
41. Royal College of Pathologists. Pathology Reporting of Breast Disease. NHSBSP Publication no. 58. NHS Cancer Screening Programmes: Sheffield, 2005; 16-17.
42. Agranoff D, Fernandez-Reyes D, Papadopoulos MC, Rojas SA, Herbster M, Loosemore A et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 2006; 368: 1012-1021.
43. Berrar D, Bradbury I, Dubitzky W. Avoiding model selection bias in small-sample genomic datasets. Bioinformatics 2006; 22: 1245-1250.
44. Degnim AC, Reynolds C, Pantvaidya G, Zakaria S, Hoskin T, Barnes S et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg 2005; 190: 543-550.
45. Smidt ML, Kuster DM, van der Wilt GJ, Thunnissen FB, Van Zee KJ, Strobbe LJ. Can the Memorial Sloan-Kettering Cancer Center nomogram predict the likelihood of nonsentinel lymph node metastases in breast cancer patients in the Netherlands? Ann Surg Oncol 2005; 12: 1066-1072.
46. Newman EL, Kahn A, Diehl KM, Cimmino VM, Kleer CA, Chang AE et al. Does the method of biopsy affect the incidence of sentinel lymph node metastases? Breast J 2006; 12: 53-57.
47. Bleiweiss IJ, Nagi CS, Jaffer S. Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma.J Clin Oncol 2006; 24: 2013-2018.
48. Specht MC, Kattan MW, Gonen M, Fey J, Van Zee KJ. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 2005; 12: 654-659.